Mayne Pharma Group Limited (MYX.AX)

AUD 4.85

(-2.02%)

Total Debt Summary of Mayne Pharma Group Limited

Mayne Pharma Group Limited's latest annual total debt in 2024 was 31.64 Million AUD , down -18.28% from previous year.
Mayne Pharma Group Limited's latest quarterly total debt in 2024 FY was 38.82 Million AUD , down -18.28% from previous quarter.
Mayne Pharma Group Limited reported annual total debt of 47.5 Million AUD in 2023, down -88.52% from previous year.
Mayne Pharma Group Limited reported annual total debt of 413.66 Million AUD in 2022, up 19.27% from previous year.
Mayne Pharma Group Limited reported quarterly total debt of 38.82 Million AUD for 2024 FY, down -18.28% from previous quarter.
Mayne Pharma Group Limited reported quarterly total debt of 31.64 Million AUD for 2024 Q4, down 0.0% from previous quarter.

Annual Total Debt Chart of Mayne Pharma Group Limited (2024 - 2007)

Historical Annual Total Debt of Mayne Pharma Group Limited (2024 - 2007)

Year	Total Debt	Total Debt Growth
2024	31.64 Million AUD	-18.28%
2023	47.5 Million AUD	-88.52%
2022	413.66 Million AUD	19.27%
2021	346.81 Million AUD	-12.87%
2020	398.04 Million AUD	7.76%
2019	369.38 Million AUD	-1.28%
2018	374.19 Million AUD	9.98%
2017	340.24 Million AUD	342.83%
2016	76.83 Million AUD	24.42%
2015	61.75 Million AUD	28.58%
2014	48.03 Million AUD	2.85%
2013	46.69 Million AUD	0.0%
2012	- AUD	-100.0%
2011	2.33 Million AUD	-72.85%
2010	8.61 Million AUD	387579.03%
2009	2222.00 AUD	-60.01%
2008	5556.00 AUD	-37.5%
2007	8889.00 AUD	0.0%

Year	Total Debt	Total Debt Growth
2024 Q2	36.57 Million AUD	0.0%
2024 FY	38.82 Million AUD	-18.28%
2024 Q4	31.64 Million AUD	0.0%
2023 FY	47.5 Million AUD	-88.52%
2023 Q4	47.5 Million AUD	0.0%
2023 Q2	81.23 Million AUD	0.0%
2022 Q2	387.26 Million AUD	0.0%
2022 Q4	413.66 Million AUD	0.0%
2022 FY	413.66 Million AUD	19.27%
2021 Q2	352.1 Million AUD	0.0%
2021 Q4	346.81 Million AUD	0.0%
2021 FY	346.81 Million AUD	-12.87%
2020 FY	398.04 Million AUD	7.76%
2020 Q4	398.04 Million AUD	0.0%
2020 Q2	388.69 Million AUD	0.0%
2019 Q2	394.57 Million AUD	0.0%
2019 FY	369.38 Million AUD	-1.28%
2019 Q4	369.38 Million AUD	0.0%
2018 Q2	359.08 Million AUD	0.0%
2018 Q4	374.19 Million AUD	0.0%
2018 FY	374.19 Million AUD	9.98%
2017 Q2	313.07 Million AUD	0.0%
2017 FY	340.24 Million AUD	342.83%
2017 Q4	340.24 Million AUD	0.0%
2016 Q4	77.67 Million AUD	0.0%
2016 FY	76.83 Million AUD	24.42%
2016 Q2	64.79 Million AUD	0.0%
2015 FY	61.75 Million AUD	28.58%
2015 Q2	58.87 Million AUD	0.0%
2015 Q4	61.75 Million AUD	0.0%
2014 Q2	55.53 Million AUD	0.0%
2014 Q4	48.03 Million AUD	0.0%
2014 FY	48.03 Million AUD	2.85%
2013 Q4	46.69 Million AUD	0.0%
2013 Q2	- AUD	0.0%
2013 FY	46.69 Million AUD	0.0%
2013 Q3	- AUD	0.0%
2012 FY	- AUD	-100.0%
2012 Q4	- AUD	0.0%
2011 Q4	2.33 Million AUD	0.0%
2011 FY	2.33 Million AUD	-72.85%
2010 Q4	8.61 Million AUD	0.0%
2010 FY	8.61 Million AUD	387579.03%
2009 Q4	2222.00 AUD	0.0%
2009 FY	2222.00 AUD	-60.01%
2008 FY	5556.00 AUD	-37.5%
2008 Q4	5556.00 AUD	0.0%
2007 Q4	8889.00 AUD	0.0%
2007 FY	8889.00 AUD	0.0%

Peer Total Debt Comparison of Mayne Pharma Group Limited

Name	Total Debt	Total Debt Difference
Firebrick Pharma Limited	- AUD	-Infinity%